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The feasibility of opportunistic screening of urogenital 
infections with Chlamydia trachomatis was assessed 
in a cross-sectional study in 2012, in two cantons of 
south-western Switzerland: Vaud and Valais. Sexually 
active persons younger than 30 years, not tested for 
C. trachomatis in the last three months, were invited 
for free C. trachomatis testing by PCR in urine or self-
applied vaginal swabs. Of 2,461 consenting partici-
pants, 1,899 (77%) were women and all but six (0.3%) 
submitted a sample. Forty-seven per cent of female 
and 25% of male participants were younger than 20 
years. Overall, 134 (5.5%) of 2,455 tested participants 
had a positive result and were followed up. Seven per 
cent of all candidates for screening were not invited, 
10% of invited candidates were not eligible, 15% of 
the eligible candidates declined participation, 5% of 
tested participants testing positive were not treated, 
29% of those treated were not retested after six 
months and 9% of those retested were positive for 
C. trachomatis. Opportunistic C. trachomatis testing 
proved technically feasible and acceptable, at least if 
free of charge. Men and peripheral rural regions were 
more difficult to reach. Efforts to increase testing and 
decrease dropout at all stages of the screening proce-
dure are necessary.
Introduction
Chlamydia trachomatis is a frequent cause of sexu-
ally transmitted urogenital infections [1]. Carriers with 
asymptomatic infection are a difficult to reach reser-
voir promoting transmission to their sexual partners 
[2]. Complications, although rarely life threatening, 
can be substantial, especially for women. They include 
pelvic inflammatory disease, chronic abdominal pain, 
ectopic pregnancy, tubal sterility [2] and possibly a 
higher risk for adverse pregnancy outcomes [3,4]. 
Rates of Chlamydia-related complications in a given 
population correlate with the prevalence of chlamydial 
infection [5]. Treatment of urogenital infections caused 
by C. trachomatis can prevent complications, at least in 
the short term [6,7]. The pooled risk ratio for all-cause 
pelvic inflammatory disease after one year of follow-
up in women invited to have C. trachomatis screening 
in four randomised controlled trials was 0.64 (95% 
confidence interval (CI): 0.45–0.90) [2]. Complications 
may occur despite regular screening at fixed intervals 
because of infection after treatment or during screen-
ing intervals [8,9]. It has also been hypothesised that 
early treatment may impede development of immunity 
and favour future re-infection [10,11].
Following a decline in the late 1980s and early 1990s, 
laboratory notifications of infections with C. tra-
chomatis in Switzerland have more than quadrupled 
since 2000 [1,12]. In 2003, most infections were diag-
nosed by gynaecologists, hospital services and pri-
mary healthcare physicians [13]. One study, published 
in 1989, found a positive culture rate of 18% in 600 
women aged 18 to 55 years at a sexual health centre in 
Lausanne [14]. Half of these women (49%) were symp-
tomatic. More recent studies in Switzerland using PCR 
testing found lower rates: In 1998, 1% of 817 pregnant 
women and 2.8% of 772 other sexually active women 
were found to be PCR-positive for Chlamydia by their 
gynaecologist [15]. In 2006 and 2007, 1.2% of 517 male 
Swiss military recruits with a mean age of 20 years 
were found by PCR to be infected [16], as were 7.3% of 
386 healthy pregnant women in the period from 2006 
to 2009 [4].
The European Centre for Disease Prevention and Control 
(ECDC) recommends implementation of C. trachomatis 
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control using a strategy of four levels: primary pre-
vention, case management, opportunistic testing and 
systematic screening [2,17]. In Switzerland, a national 
programme for primary prevention of human immuno-
deficiency virus (HIV) infection was started in 1987, 
and subsequently widened in 2011 to all sexually trans-
mitted infections (STI) [18]. A national guideline for 
case management of STI including C. trachomatis was 
published in 2011 [19], but no recommendations exist 
for testing. A C. trachomatis test with administration 
fees costs CHF 119 (EUR 111), not including any medical 
consultation fees. These costs are reimbursed by basic 
insurance when the yearly medical costs exceed CHF 
300 (EUR 281). The young and healthy without other 
health expenses therefore pay screening costs directly.
This study explores the feasibility of opportunistic 
testing for C. trachomatis control, the third level in the 
ECDC recommendations. From a public health perspec-
tive, feasibility should be examined at all stages of 
programme implementation, from societal to individual 
level. These may be conceptualised as political accept-
ance, provider compliance, target population accept-
ance, and user compliance. We report on feasibility at 
all of these levels.
Methods
The study was conducted in two cantons with a com-
bined population of 1 million, situated in the south-
western part of Switzerland: Valais and Vaud. The 
capital cities of Vaud and Valais, Lausanne and Sion, 
have 142,000 and 42,000 inhabitants, respectively. 
Both cantons have rural districts, some of them 
extending into partially remote alpine valleys. Most 
districts are French speaking; German is spoken in the 
eastern districts of Valais (about one in twelve of the 
total study population).
Free C. trachomatis testing in first-void urine or, for 
women according to personal preference, self-applied 
vaginal swabs, was offered from February to August 
2012 to all persons younger than 30 years in public 
health services representative of the whole territory. 
These included all centres of two public cantonal sexual 
health networks (eight in Vaud, including seven with an 
on-site physician; five in Valais, none with on-site phy-
sicians) and, for comparison, two infectious disease (ID) 
outpatient clinics (Sion and Visp, Valais). As the num-
ber of available tests was restricted by the allocated 
study budget, the recruitment period was shortened in 
centres with high testing activity in order to allow test-
ing in centres with lower throughput. Every candidate, 
defined as a female or male person visiting a screening 
centre or clinic, was given an invitation (invited candi-
dates) for screening together with an information sheet 
about C. trachomatis. Individuals who had never had 
sexual intercourse or who had been screened for uro-
genital C. trachomatis infection less than three months 
previously were excluded. Participation was confirmed 
by written consent. Consenting participants (Figure 
1) were given a questionnaire on demographics and 
sexual behaviour and a self-sampling kit with illus-
trated instructions on how to sample urine and, for 
women, how to take a vaginal swab.
The urine and vaginal swab samples of tested par-
ticipants were collected at the screening centre and 
centrally analysed by PCR. In Valais, a commercial 
kit (Roche Diagnostics, Switzerland) was used by the 
Central Institute laboratory for molecular biology, Sion 
(Institut Central Hôpital du Valais; ICHV). In Vaud, a 
validated in-house C. trachomatis PCR [20] was used 
by the Institute of Microbiology of the University of 
Lausanne (IMUL).
According to the participant’s choice, treatment for 
Chlamydia was organised with their primary care phy-
sician or gynaecologist, at the screening centre or at 
the nearest centre with an on-site physician. Partner 
notification was recorded for each infection. Screening 
for other STI and preventive counselling were left to 
the discretion of the treating physician. A control visit, 
involving a second free test for C. trachomatis, was 
scheduled for cases with documented infection six 
months after treatment. Each screening centre had to 
document for each candidate all the steps up to either 
a negative screening result or, in the case of a positive 
result, the negative control test result six months after 
treatment. The first step not fulfilled was noted as the 
point of drop-out.
The study protocol was submitted and accepted by 
the ethical committee in each participating canton 
(Valais: no. CCVEM 023/11; Vaud: no. 281/11). The 
study was supervised by a committee of representa-
tives of the participating screening centres, the pub-
lic health authorities and the testing laboratories. It 
also included a research specialist from the University 
Institute of Social and Preventive Medicine, Lausanne.
 
Descriptive statistics and comparisons (Fisher’s exact 
test for 2x2 tables (proportions), chi-square test for 
other tables and Kruskal-Wallis test for continuous 
variables) and other calculations were produced with 
open source R, version 3.0.3 [21]. Confidence intervals 
for proportions were calculated with the asymptotic 
definition for confidence limits on a single proportion 
using the Central Limit Theorem (binom.test function in 
package binom).
Results
Results regarding each successive level of the study 
flow are summarised in Figure 1.
Provider compliance, assessed by rates of screen-
ing invitations, and target population acceptance, 
assessed by rates of participation, could be monitored 
in 14 of the 15 screening centres, totalling 2,995 can-
didates between February and December 2012. One 
centre did not consistently distinguish between non-
invitation and non-participation and was therefore 
excluded from this part of the analysis. This centre was 
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Figure 1
Study flowchart, Chlamydia trachomatis screening, Switzerland, 2012 (n = 2,995)
198 not invited (7%)
384 did not consent (15%)
127 treatments
2,176 informed
132 informed
108 partner notifications
79 informed
2 not informed (1%)
5 not treated (4%)
24 no partner 
notification (19%)
37 not retested (29%)
8 positive for C.t . (9%)
3 not informed (3%)
45 not informed (6%)
6 did not give sample (0.3%)
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Candidates for screening: 2,995 (Vaud: 1,642, Valais: 1,353)
Invited candidates: 2,797 (Vaud: 1,631, Valais: 1,166) 
Eligible candidates: 2,531 (Vaud: 1,443, Valais: 1,088)
2,147 (Vaud: 1,247, Valais: 900)
+ 314 from 15th centrea (Valais: 314)
= 2,461 consenting participants
Tested participants: 2,455 (Vaud: 1,245, Valais: 1,210)
2,321 negative (Valais: 1,148, Vaud: 1,173) 134 positive (Valais: 62, Vaud: 72)
90 tested at 6 monthsb
82 negative at 6 monthsc
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266 not eligible (10%)
• Older than 30 years old: 4
• Never had sexual intercourse: 162
• Tested for C.t. in the past three months: 100
C.t.: Chlamydia trachomatis.
a  One of 15 centres did not consistently distinguish between non-invitation and non-participation and was excluded from the inclusion part of 
analysis. This centre provided an additional 314 consenting participants included in screening and follow up.
b  Control test by PCR at 6 months after treatment.
c  Negative control test by PCR at six months after treatment.
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Table 1
Reasons given for declining Chlamydia trachomatis screening by 269 of 384 persons invited in 14 of 15 screening centres, 
Switzerland, 2012 (n = 269)
Reason Vaud Valais All
Not interested / not in the mood 46 (30%) 34 (30%) 80 (30%)
No time 11 (7.1%) 37 (32%) 48 (18%)
Believes to be at too low risk to justify screening 14 (9.1%) 10 (8.7%) 24 (8.9%)
Long-term stable relationship 16 (10%) 2 (1.7%) 18 (6.7%)
Believes not to be at risk (always protected sexual intercourse or mutual first partners) 9 (5.8%) 6 (5.2%) 15 (5.6%)
C. trachomatis screening already done before study 3 (1.9%) 5 (4.3%) 8 (3,0%)
Doesn’t speak the language (French or German) 4 (2.6%) 2 (1.7%) 6 (2.2%)
Cannot urinate 5 (3.2%) 2 (1.7%) 7 (2.6%)
Wishes parental advice first 5 (3.2%)  0 (0%) 5 (1.9%)
Wants to go somewhere else for screening 3 (1.9%) 2 (1.7%) 5 (1.9%)
Other reasons 38 (25%) 15 (13%) 53 (20%)
Total 154 (100%) 115 (100%) 269 (100%)
No reason given 115
Total of declined invitations 384
The invited persons declining screening were encouraged to write down their reasons not to participate. These reasons in free text were 
grouped together.
Figure 2
Age distribution of tested participants, Chlamydia trachomatis screening, Switzerland, 2012 (n = 2,455)
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910 (48%) of all female tested participants were younger than 20 years, 129 (6.8%) younger than 16 years.
164 (29%) of all male tested participants were younger than 20 years, 17 (3.0%) younger than 16 years.
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organised as a walk-in clinic and was overwhelmed 
by candidates. Its recruitment rate was only 314 par-
ticipants for 1,522 candidates (21%), compared with 
2,147 of 2,995 (72%) for the 14 other centres combined 
(p < 0.001). In these 14 centres, 2,797 of the 2,995 can-
didates (93%) were invited for screening; the individual 
centres’ invitation rates ranged from 78% to 100%. Of 
the 2,797 invited candidates, 2,531 (90%) were eli-
gible and 2,147 of those (85%) accepted screening. 
Acceptance rates were the same (85%) for both sexes 
(with seven (0.3%) missing answers) and differed little 
by age group (< 20 years: 920/1,069 (86%); 20 to < 25 
years: 748/844 (89%); 25 to 29 years: 478/553 (86%); 
missing answers: 65 (2.6%); p > 0.05). Acceptance 
rates were highest in those primarily consulting for STI 
screening or diagnosis, with or without symptoms of 
STI, or for other reasons related to sexual health, with 
rates of 659 of 704 (94%) and 1,165 of 1,318 (88%), 
respectively. Of 383 persons consulting for reasons 
unrelated to sexual health, 300 (78%) accepted screen-
ing (p < 0.001). 126 answers (5%) were missing, more 
frequently in those declining screening (27%) than in 
those accepting (1%). Acceptance rates per screen-
ing centre ranged from 58% to 91% and were higher 
in French-speaking centres than in German-speaking 
ones (2,083/2,432 (86%) vs 64/99 (65%); p < 0.001). Of 
Table 2
Characteristics of tested participants and questionnaire answers, Chlamydia trachomatis screening, Switzerland, 2012 
(n = 2,455)
Vaud Valais All
Number of answers (total) 1,245 1,210
p value
2,455
Proportion 
of positive 
answers
Positive/
total 
answers
Proportion 
of positive 
answers
Positive/
total 
answers
Proportion 
of positive 
answers
Positive/
total 
answers
Demographic information
Female sex 88% 1,091/1,245 66% 804/1,210 < 0.0001 77% 1,895/2,455
Women: pregnant 3.0% 33/1,085 4.8% 38/790 0.051 3.8% 71/1,875
Mean age (years) 21.2 n = 1,245 21.6 n = 1,210 0.047 21.4 n = 2,455
Median age (years) 20.6 n = 1,245 21 n = 1,210 0.047 21.4 n = 2,455
≤ 16 years-old 5.9% 73/1,245 6% 73/1,210 > 0.1 5.9% 146/2,455
≤ 20 years-old 45% 559/1,245 43% 515/1,210 > 0.1 44% 1,074/2,455
Motive for consultation
Sexual health 67% 819/1,228 32% 380/1,203 < 0.0001 49% 1,199/2,431
STI screening 23% 285/1,228 38% 462/1,203 < 0.0001 31% 747/2,431
Pregnancy 1.5% 18/1,228 5.1% 61/1,203 < 0.0001 3.3% 79/2,431
Pregnancy interruption 1.1% 14/1,228 1.2% 14/1,203 > 0.1 1.2% 28/2,431
Symptoms of active STI 4.4% 54/1,228 1.2% 15/1,203 < 0.0001 2.8% 69/2,431
Travela NA NA 15% 177/1,203 < 0.0001 7.3% 177/2,431
No link to sexual healthb 0.41% 5/1,228 4.4% 53/1,203 < 0.0001 2.4% 58/2,431
Other 2.7% 33/1,228 3.4% 41/1,203 > 0.1 3% 74/2,431
Questionnaire
Heard of C. trachomatis 49% 605/1,243 34% 407/1,207 < 0.0001 41% 1,012/2,450
Subjective symptoms of STI present 6.4% 79/1,236 5.1% 61/1,201 > 0.1 5.7% 140/2,437
Tested for C. trachomatis 22% 267/1,241 3.9% 47/1,202 < 0.0001 13% 314/2,443
Born in Switzerland vs other 73% 908/1,243 81% 975/1,208 < 0.0001 77% 1,883/2,451
Resident in a commune < 10,000 inhabitants 52% 628/1,210 64% 756/1,183 < 0.0001 58% 1,384/2,393
Mean age at first sexual intercourse (years) 16.4 n = 1,240 16.4 n = 1,196 > 0.1 16.4 n = 2,436
Median age at first sexual intercourse (years) 16 n = 1,240 16 n = 1,196 > 0.1 16.4 n = 2,436
Having had heterosexual intercourse 99% 1,210/1,228 97% 1,153/1,185 0.044 98% 2,363/2,413
Having had homosexual intercourse 5.3% 65/1,222 6.4% 75/1,175 > 0.1 5.8% 140/2,397
Mean number of sexual partners in the past 6 months 1.8 n = 1,238 1.7 n = 1,200 > 0.1 1.7 n = 2,438
Median number of sexual partners in the past 6 months 1 n = 1,238 1 n = 1,200 > 0.1 1.7 n = 2,438
NA: not applicable; STI: sexually transmitted infection.
Statistic tests (comparisons between the two cantons): for proportions (2x2): Fisher’s exact test; for continuous data: Kruskal-Wallis. p 
values are not corrected for multiple testing. Totals can be lower than those in the column header because of missing answers or counts in 
subpopulations.
a Valais: travellers coming for vaccination (infectious disease clinic in Sion).
b Valais: mostly patients treated for other infectious diseases such as HIV and hepatitis C (infectious disease clinic in Sion).
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the 384 persons declining screening, 269 gave a rea-
son. These were grouped into categories, as shown in 
Table 1.
Including data from all 15 centres, there were a total of 
2,461 consenting participants (Vaud: n = 1,247, Valais: 
n = 1,214). Of these, 2,455 (99.8%) provided a test 
sample and a questionnaire. Of the tested participants, 
1,895 (77%) were women (Vaud: 1,091 (88%), Valais: 
804 (66%)), of whom 358 (19%; Vaud: 299 (28%), 
Valais: 59 (7.3%)) chose to supply a vaginal swab and 
1,537 (81%) chose to supply first-void urine. Age distri-
bution, demographic data, reason for consultation and 
other information in the questionnaire are provided in 
Figure 2 and Table 2.
A mean of 149 consenting participants (125 women, 24 
men) were tested per week when all centres were open. 
Extrapolated over 52 weeks, assuming access to test-
ing under the same conditions and 82% of the popula-
tion sexually active (personal communication: Lociciro 
S, Spencer B, July 2014), 3.7% (6.7% of women, 1.2% 
of men) of the sexually active population aged between 
12 and 29 years in 2012 in the study region [22] would 
have been tested.
A PCR test result was available for all 2,455 samples 
(Figure 1). 134 samples (5.5%, 95% CI: 4.6–6.4; Vaud 
5.8%, Valais 5.1%) proved to be positive for C. tra-
chomatis: 112 of 1,895 women (5.9%, 95% CI: 4.8–7.0) 
and 22 of 560 men (3.9%, 95% CI: 2.3–5.5). The median 
age and youngest age with a positive screening result 
were 20.6 and 14.0 years, respectively, for female 
participants and 23.5 and 17.0 years, respectively, for 
male participants. Infection rates in women were sig-
nificantly higher at age 19 to 22 years compared with 
those younger or older (Figure 3) and peaked in the age 
group 20 to 22 years (9.9%, 95% CI: 6.6–13.3). Twelve 
infections were found in 88 women (14%, 95% CI: 6.4–
20.8) who were 13 years-old or younger at their first 
sexual intercourse. Lower numbers preclude a similar 
analysis for male participants.
A treatment consultation was arranged for 127 of 134 
participants with documented infection (95%). Of 
these, 90 (71%) were retested after six months, with 82 
(91%) negative results. Some 108 partners of 134 par-
ticipants with infection (81%) were notified, 94 (87%) 
by the participants themselves and 14 (13%) by the 
screening centre.
Infection rates were similar for different educational 
levels, districts of residence, sizes of population of 
Figure 3
Chlamydia trachomatis infection rate by age group, Switzerland, 2012 (n = 2,455)
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the town of residence (≥ 10,000 vs < 10,000 inhabitants) 
and country of birth (Switzerland vs other). No infec-
tion was found in 66 female participants indicating no 
sexual partner in the last six months. The four districts 
with only one, seven, 13 and 39 tested participants 
reported zero infections. Infection rates were higher for 
sexual health patients (including general counselling, 
gynaecology checks, pregnancy, STI screening) than 
for patients in travel clinics and other sources, with 
infection rates of 127 of 2,122 (6.0%, 95% CI 5.0%–
7.0%), two of 177 (1.1%, 95% CI 0–2.7%) and five of 
156 (3.2%, 95% CI 0.4–6.0%), respectively. Patients in 
travel clinics were older than sexual health patients at 
screening (median age: 24.8 vs 20.6 years, p < 0.0001) 
and at their first sexual intercourse (median age: 17 vs 
16 years, p < 0.01). Of all 134 infections, 63 (47%) were 
found in participants indicating one sexual partner in 
the last six months. For both sexes, the infection rate 
increased with an increasing number of sexual partners 
in the six months before screening (Figure 4), with 19 
infections in 169 participants (11%, 95% CI: 6.5–16.0) 
indicating more than three sexual partners in the last 
six months. Of 140 (5.7%) participants reporting symp-
toms of STI, 16 (11%) had a positive screening test.
In 2012, 974 Chlamydia infections were notified by lab-
oratories in the study region (not including those found 
in this study). Extrapolating the study experience over 
one year, 375 infections in women (infection rate 5.9%) 
and 47 in men (infection rate 3.9%) could have been 
diagnosed by the study test centres, increasing the 
study region’s total number of diagnosed infections by 
422 infections (43%).
Discussion
Independently of the on-site presence of a physician, 
testing for urogenital infection with C. trachomatis in 
sexually active adults younger than 30 years using self-
applied urine samples, or, for women, vaginal swabs, 
proved technically feasible in the two Swiss cantons 
under study. When offered at no cost, C. trachomatis 
testing proved acceptable overall, despite the fact that 
almost half of participants had never previously heard 
of C. trachomatis infection (Table 2). Only 31% of all par-
ticipants were consulting for HIV/STI-screening, mostly 
anonymous HIV-screening. C. trachomatis screening 
can be proposed successfully in situations other than 
STI screening, particularly those related to sexual 
health, but also in those a priori unrelated to sexual 
health such as travel counselling, with acceptance 
rates that were not much lower (78%), independently 
of factors such as age and sex. The German-speaking 
region, a more secluded and rural mountain commu-
nity, had not only a lower acceptance rate, but sig-
nificantly less consultation activity. This may be best 
explained by cultural factors resulting in less demand 
and geographical factors impeding easy access to test-
ing facilities. With the exception of one walk-in facility, 
it was possible to integrate Chlamydia screening into 
the centres’ daily workload without adjustment in the 
workforce or increased consultation times. The infor-
mation sheet and illustrated instructions for sampling 
proved helpful. C. trachomatis PCRs exhibit similar 
positivity rates in urine and vaginal swabs, but urine 
sampling was preferred over vaginal swabs by ca 80% 
of women.
In this study, infection rates varied between 1% 
and 11%, depending on already known risk factors, 
and were not substantially different from infection 
rates reported in Switzerland and Europe [4,15,16]. 
Population-based studies in European Union Member 
States report infection rates between < 1% and 10% for 
women and between < 1% and 6% for men, depending 
on country and characteristics of the study popula-
tion [2]. The National Chlamydia Screening Programme 
(NCSP) in the United Kingdom (UK) reported an infec-
tion rate of 7.7% in 2012 [23] and a Dutch pilot study 
(2008–2011) a rate of 4.3% [23,24]. Infection rates 
for men at similar risk are consistently lower than for 
women of the same age and level of risk [2,23,24]. Our 
study did not find different infection rates in individu-
als born in Switzerland vs those born elsewhere.
Nearly half of the female participants were younger 
than 20 years and the study participants had a pro-
file of low to medium risk, with a median of one sex 
partner in the six months before screening. Half of all 
infections were therefore diagnosed in low-risk par-
ticipants with only one sexual partner in the past six 
months. Although the questionnaire identified factors 
representing a relatively higher risk, such as presence 
of symptoms (11% positivity rate), being female and in 
the peak age group (10%) or having more than three 
sex partners in the six months before screening (11%), 
Figure 4
Chlamydia trachomatis infection rate by number of sex 
partners in the six months before screening, Switzerland, 
2012 (n = 2,438; 17 missing answers)
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the only characteristic specific to individuals with no 
risk of infection was having had no sex partner in the 
past six months (having been sexually active before). 
Risk-based selection algorithms aiming at improved 
cost effectiveness [25] may therefore miss a substan-
tial number of infections occurring in parts of the popu-
lation associated with lower risk.
Limitations and challenges
Despite C. trachomatis screening proving to be techni-
cally feasible and reliable and treatment being simple 
and affordable, important obstacles remain. Despite 
near universal insurance coverage, access to screen-
ing for C. trachomatis in Switzerland is limited owing 
to a mandatory minimal yearly participation of CHF 300 
(EUR 280). The high cost of a C. trachomatis test needs 
to be reviewed in order to allow affordable access, 
especially for adolescents. Men proved to be more dif-
ficult to reach in this context, constituting only 23% of 
the sample. Male participants were older than female 
participants and the proportion younger than 20 years 
was significantly lower. In the NCSP, men were more 
likely to order self-applied tests on the Internet than 
to visit a clinic for testing, and the number of tests 
ordered in this way increased from <1% to 6% of all 
tests between 2006 and 2010 [26]. A screening pro-
gramme in 13 schools in New Orleans, United States, 
in 1995 to 2005 showed up to 49% repeated testing 
in male students (with parental consent) [27]. Of men 
aged 18 to 35 years in a survey in the UK, 75% had 
seen their family doctor in the last year, without rel-
evant differences between different age groups among 
the 18 to 35-year-olds, providing general practitioners 
with occasions for opportunistic STI screening [28]. In 
the NCSP, 9% of male 15 to 24 years-olds were tested 
by their general practitioner. Extrapolated over one 
year, the centres in our study alone would have tested 
a small proportion, ca 4%, of the 12 to 29 years-olds 
in the study region [1]. Such testing activity would 
thus have little impact on Chlamydia transmission or 
its prevalence on a population level. In Switzerland, 
gynaecologists, hospitals services and primary care 
physicians notified most of all notified C. trachomatis 
infections in 2003 [13], but those healthcare providers 
were not included in this study. School-initiated home 
testing in post-obligatory schools (age 16 years and 
upwards) was initially intended. The school authorities 
in one canton declined participation, which shows a 
limitation on political grounds.
Nineteen per cent of all partners of tested partici-
pants with a positive result could be notified. Most 
partner notifications were only documented by asking 
the study participants. Whether sex partners actually 
received treatment was not assessed. Ascertaining if 
all partners are treated is a difficult challenge [29] and 
would also have been difficult in this study.
Conclusions
C. trachomatis notifications in Switzerland have 
increased from 2,123 in 1999 to 9,701 in 2014. It remains 
unknown if this trend corresponds to an increasing 
incidence or other factors such as increased screening 
or an increased notification rate. Based on our results 
four main statements can be made to inform the public 
health authorities of Valais and Vaud regarding preven-
tive measures for urogenital C. trachomatis infection 
and its complications. Firstly, C.  trachomatis is pre-
sent in the study region and therefore screening and 
efficient treatment would be desirable to prevent com-
plications, no less than in other countries with similar 
infection rates. Secondly, as this study shows that C. 
trachomatis screening in existing sexual health centres 
in south-western Switzerland is technically feasible, 
these screening services can also be used for epide-
miological investigation. Thirdly, C. trachomatis testing 
at low and affordable cost could promote use by those 
at risk. Finally, more screening opportunities need to 
be created, especially for difficult to reach populations 
such as men or people living in regions with difficult 
access for geographical reasons, and drop–outs dur-
ing the screening and follow-up process need to be 
decreased.
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